Amlodipine Besylate (Amlodipine Besylate) Patent Expiration, LOE Window & CMS Spending

Amlodipine Besylate (Amlodipine Besylate) by Synthon: Off-Patent Genericized (AB Competition), 19 AB generics, $395.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSynthon
FDA Application & PathwayN022026 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$395.6M
2024 Medicare Part D Spend$315.7M
2024 Medicaid Spend$79.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel